Form 4: Fulgent Genetics CFO Paul Kim Reports Tax-Related Stock Disposition

Fulgent Genetics' CFO and Treasurer, Paul Kim, reported the disposition of 2,743 shares of common stock valued at $18.37 per share to cover tax withholding obligations from restricted stock unit vesting.

Summary

• Paul Kim, the Chief Financial Officer and Treasurer of Fulgent Genetics, Inc. (FLGT), reported a transaction involving the company's common stock.
• On July 26, 2025, Mr. Kim disposed of 2,743 shares of Fulgent Genetics Common Stock.
• The shares were disposed of at a price of $18.37 per share.
• This disposition was a 'F' transaction code, indicating shares were withheld by the issuer to satisfy tax withholding obligations.
• The tax obligations arose from the vesting of certain restricted stock units (RSUs) that were assumed as part of a merger agreement dated November 7, 2022.
• Following this transaction, Mr. Kim beneficially owns 339,828 shares of Fulgent Genetics Common Stock directly.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged sale plan.

Sentiment

Score: 5

Explanation: The sentiment is neutral. This is a routine, non-discretionary transaction for tax purposes related to equity compensation, which is a common occurrence for executives and does not reflect a change in management's view of the company's prospects.

Positives

• The transaction is a routine tax withholding event, not a discretionary sale by management, which suggests no negative sentiment from the insider.
• The disposition was part of a pre-arranged Rule 10b5-1(c) plan, indicating a structured and compliant approach to equity compensation.

Negatives

• A reduction of 2,743 shares in the CFO's direct beneficial ownership, although for tax purposes, represents a decrease in his direct stake.

Future Outlook

The filing does not provide any forward-looking statements or guidance beyond the details of the reported transaction.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction related to equity compensation and tax obligations, common across all industries for publicly traded companies. It does not provide specific insights into broader industry trends or competitive landscape.

Comparison to Industry Standards

• The disposition of shares to cover tax withholding upon RSU vesting is a standard practice for executive compensation in publicly traded companies, aligning with common industry norms for managing equity awards.
• The use of a Rule 10b5-1(c) plan for this transaction is also a widely adopted best practice for insiders to manage stock sales in a compliant and pre-scheduled manner, similar to practices at companies like Illumina (ILMN) or Exact Sciences (EXAS) in the diagnostics and genetics sector.

Stakeholder Impact

• Shareholders: The transaction represents a minor, non-discretionary reduction in the CFO's direct shareholding, which is unlikely to have a material impact on overall shareholder sentiment or company valuation.
• Employees: The vesting of restricted stock units and subsequent tax withholding is a standard component of executive compensation, reflecting the company's ongoing equity incentive programs.

Key Dates

Keywords

Fulgent Genetics, FLGT, Paul Kim, CFO, Treasurer, Form 4, SEC filing, insider transaction, stock disposition, restricted stock units, RSU vesting, tax withholding, Rule 10b5-1 plan